825 related articles for article (PubMed ID: 26932327)
1. SUMO-regulated mitochondrial function in Parkinson's disease.
Guerra de Souza AC; Prediger RD; Cimarosti H
J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
[TBL] [Abstract][Full Text] [Related]
2. SUMO and Parkinson's disease.
Eckermann K
Neuromolecular Med; 2013 Dec; 15(4):737-59. PubMed ID: 23979994
[TBL] [Abstract][Full Text] [Related]
3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
4. Current perspective of mitochondrial biology in Parkinson's disease.
Ammal Kaidery N; Thomas B
Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
[TBL] [Abstract][Full Text] [Related]
5. Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha.
Siddiqui A; Rane A; Rajagopalan S; Chinta SJ; Andersen JK
Neurobiol Dis; 2016 Sep; 93():115-20. PubMed ID: 27185595
[TBL] [Abstract][Full Text] [Related]
6. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
7. Determinants of dopaminergic neuron loss in Parkinson's disease.
Surmeier DJ
FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
[TBL] [Abstract][Full Text] [Related]
8. [The role of parkin in Parkinson's disease].
Miklya I; Göltl P; Hafenscher F; Pencz N
Neuropsychopharmacol Hung; 2014 Jun; 16(2):67-76. PubMed ID: 24978049
[TBL] [Abstract][Full Text] [Related]
9. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease.
Thomas B; Beal MF
Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation.
Zhong N; Xu J
Hum Mol Genet; 2008 Nov; 17(21):3357-67. PubMed ID: 18689799
[TBL] [Abstract][Full Text] [Related]
12. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
[TBL] [Abstract][Full Text] [Related]
13. Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease.
Dolgacheva LP; Berezhnov AV; Fedotova EI; Zinchenko VP; Abramov AY
J Bioenerg Biomembr; 2019 Jun; 51(3):175-188. PubMed ID: 31054074
[TBL] [Abstract][Full Text] [Related]
14. Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neurons.
Zheng L; Bernard-Marissal N; Moullan N; D'Amico D; Auwerx J; Moore DJ; Knott G; Aebischer P; Schneider BL
Hum Mol Genet; 2017 Feb; 26(3):582-598. PubMed ID: 28053050
[TBL] [Abstract][Full Text] [Related]
15. Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease.
Ferretta A; Gaballo A; Tanzarella P; Piccoli C; Capitanio N; Nico B; Annese T; Di Paola M; Dell'aquila C; De Mari M; Ferranini E; Bonifati V; Pacelli C; Cocco T
Biochim Biophys Acta; 2014 Jul; 1842(7):902-15. PubMed ID: 24582596
[TBL] [Abstract][Full Text] [Related]
16. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
17. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
[No Abstract] [Full Text] [Related]
18. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
[TBL] [Abstract][Full Text] [Related]
19. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
20. The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
Zhang Z; Liu L; Jiang X; Zhai S; Xing D
Antioxid Redox Signal; 2016 Oct; 25(11):609-622. PubMed ID: 27267045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
